Chen et al. (2023) analyzed a large cohort of Chinese breast cancer patients and explored differences between HER2 ultra-low, HER2-null, and HER2-low expression, further contributing to the understanding of this complex classification [26]. This evidence concerns the gene ERBB2 and breast carcinoma.